Novo Nordisk CEO Sees Vast Potential in Global Weight Loss Market

Deep News04-05 13:11

Novo Nordisk A/S CEO Mike Duchastal stated in an interview that pharmaceutical companies have only just begun to tap into the global weight loss market and should focus on expanding access to their medications. The head of the company behind Wegovy and Ozempic noted that while there are 110 million obese individuals in the United States, pharmaceutical firms currently serve only 10% to 15% of this population. The need to broaden drug accessibility was one reason Novo Nordisk agreed to lower prices for medications listed on former President Donald Trump's prescription drug website, TrumpRx. Starting in January, Novo Nordisk plans to reduce the wholesale price of Wegovy in the U.S. by 50% and Ozempic by 35%. The company hopes that the launch of an oral version of Wegovy this year will help it regain market leadership after losing ground to competitor Eli Lilly. Emil Larsen, Executive Vice President of International Operations at Novo Nordisk, indicated that in price-sensitive markets like India, price reductions could form part of its competitive strategy. He added that brand recognition would also help fend off rivals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108337870?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-05 13:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108337870","market":"other","top_or_hot":-1,"title":"Novo Nordisk CEO Sees Vast Potential in Global Weight Loss Market","media":"Deep News","content":"<p>Novo Nordisk A/S CEO Mike Duchastal stated in an interview that pharmaceutical companies have only just begun to tap into the global weight loss market and should focus on expanding access to their medications. The head of the company behind Wegovy and Ozempic noted that while there are 110 million obese individuals in the United States, pharmaceutical firms currently serve only 10% to 15% of this population. The need to broaden drug accessibility was one reason Novo Nordisk agreed to lower prices for medications listed on former President Donald Trump's prescription drug website, TrumpRx. Starting in January, Novo Nordisk plans to reduce the wholesale price of Wegovy in the U.S. by 50% and Ozempic by 35%. The company hopes that the launch of an oral version of Wegovy this year will help it regain market leadership after losing ground to competitor Eli Lilly. Emil Larsen, Executive Vice President of International Operations at Novo Nordisk, indicated that in price-sensitive markets like India, price reductions could form part of its competitive strategy. He added that brand recognition would also help fend off rivals.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk CEO Sees Vast Potential in Global Weight Loss Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk CEO Sees Vast Potential in Global Weight Loss Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-05 13:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S CEO Mike Duchastal stated in an interview that pharmaceutical companies have only just begun to tap into the global weight loss market and should focus on expanding access to their medications. The head of the company behind Wegovy and Ozempic noted that while there are 110 million obese individuals in the United States, pharmaceutical firms currently serve only 10% to 15% of this population. The need to broaden drug accessibility was one reason Novo Nordisk agreed to lower prices for medications listed on former President Donald Trump's prescription drug website, TrumpRx. Starting in January, Novo Nordisk plans to reduce the wholesale price of Wegovy in the U.S. by 50% and Ozempic by 35%. The company hopes that the launch of an oral version of Wegovy this year will help it regain market leadership after losing ground to competitor Eli Lilly. Emil Larsen, Executive Vice President of International Operations at Novo Nordisk, indicated that in price-sensitive markets like India, price reductions could form part of its competitive strategy. He added that brand recognition would also help fend off rivals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1108337870","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108337870","pubTimestamp":1775365870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Novo Nordisk A/S CEO Mike Duchastal stated in an interview that pharmaceutical companies have only just begun to tap into the global weight loss market and should focus on expanding access to their...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4532":"文艺复兴科技持仓","NVOH":"Novo Nordisk A/S B Shares ADRhedged","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4599":"减肥药","NVO":"诺和诺德","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVOX":"2倍做多NVO ETF-Defiance","BK4588":"碎股"},"translate_title":"诺和诺德首席执行官看到全球减肥市场潜力巨大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":1,"NVO":1,"NVOX":1},"content_text":"Novo Nordisk A/S CEO Mike Duchastal stated in an interview that pharmaceutical companies have only just begun to tap into the global weight loss market and should focus on expanding access to their medications. The head of the company behind Wegovy and Ozempic noted that while there are 110 million obese individuals in the United States, pharmaceutical firms currently serve only 10% to 15% of this population. The need to broaden drug accessibility was one reason Novo Nordisk agreed to lower prices for medications listed on former President Donald Trump's prescription drug website, TrumpRx. Starting in January, Novo Nordisk plans to reduce the wholesale price of Wegovy in the U.S. by 50% and Ozempic by 35%. The company hopes that the launch of an oral version of Wegovy this year will help it regain market leadership after losing ground to competitor Eli Lilly. Emil Larsen, Executive Vice President of International Operations at Novo Nordisk, indicated that in price-sensitive markets like India, price reductions could form part of its competitive strategy. He added that brand recognition would also help fend off rivals.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108337870","isCrawlerRequest":true}